| |
|
|
| |
| |
| |
Monday Morning Messages
|
| |
29th July 2024
|
|
|
|
|
|
| |
|
| |
|
End of financial year deadlines
|
| |
|
|
|
|
|
| The University’s financial year ends this Wednesday 31st July 2024. In order to ensure that your payments are included in the end of year payment run, please could you ensure you meet the deadlines in the table above. If you have any queries please reach out to: finance@paediatrics.ox.ac.uk |
|
|
|
|
|
|
|
|
The Radcliffe Science Library have organised a butterfly count in the University Parks to contribute to the Big Butterfly Count. Stroll in the park, spot butterflies and contribute to conservation. All university staff and students welcome.
Date: Tuesday 30 July Time: 1-2pm |
|
|
|
|
| |
| |
|
Funding Opportunities with the TRO
|
| |
|
|
|
|
|
Please find information about funding opportunities from the Translational Research Office below:
Medical & Life Sciences Translational Fund
MLSTF funds proof-of-concept projects at the earliest stages of translation, supporting preliminary work or feasibility studies to establish the viability of an approach. In 2024, the project-managed MLSTF fund will be in excess of £1.3m to ‘pump-prime’ the translation of novel therapeutics, devices, diagnostics and other therapeutic interventions (including ‘repurposing of existing therapies’) towards clinical testing. Funding available from MLSTF will be up to £85k per project and projects should be in the region of 6-12 months in duration. Applications must be made in IRAMS (opens 10th July, deadline 1 pm on 16th September).
This MLSTF round will continue a dedicated route termed "Emerging Translational Innovators (ETI)" which provides an opportunity for early career researchers to leverage this fund as a stepping stone towards independently pursuing their translational research endeavours.
Johnson and Johnson Innovation Fund (JJIF)
The University of Oxford’s TRO (MSD) and Johnson and Johnson are pleased to announce the NEW Johnson and Johnson Innovation Fund (JJIF) which will also run under the MLSTF umbrella in 2024. Projects addressing Tissue Treg and inflammatory fibroblast modulators, gut barrier modulation, precision medicine approaches including biomarker strategies for fluid and tissue samples, and multi-specific T cell engagers for deep cell depletion are eligible to apply for this stream.
Novo Nordisk Innovation Fund (NNIF)
The Novo Nordisk Innovation Fund will run for the fifth consecutive year under the MLSTF umbrella. Projects addressing unmet patient need in diabetes and other cardiometabolic disease (obesity, cardiovascular, liver and renal disease) as well as within the field of rare endocrine and rare non-malignant blood diseases are eligible to apply for this stream. High priority will be given to projects that will identify and/or robustly validate novel targets in relevant diseases and to projects using computational approaches.
Oxford Biomedica Innovation Fund (OXBIF)
The Oxford Biomedica Innovation Fund will run alongside MLSTF for the 5th consecutive year. Projects focusing on the development of Advanced Medicinal Therapy Products are encouraged to apply. Oxford Biomedica are particularly interested in viral vector production platform technologies such as lentivirus vectors, AAV, and adenoviruses. Modality areas of interest include, vectorology, cell line development and process development.
Co-funding with Cancer Research Horizons Innovation Fund (CRHIF)
The TRO is pleased to announce the continuation of the CRHIF innovation stream this year. Cancer Research Horizons is CRUK’s Drug Discovery, Development and Commercialisation Company. This funding will specifically support the translation of CRUK-funded research projects ONLY. A key requirement for this funding strand is that the funding would need to be used to deliver key go/no-go experiments garnering data for filing a patent and/or a key inflection point to enable the next step in translational development/commercialisation. It is expected that the investigator would be willing to work with Cancer Research Horizons to develop the IP and development strategy of the novel technology.
Researchers with relevant programmes of activity are strongly encouraged to apply to these streams.
To facilitate the co-development of projects with an appropriate Johnson & Johnson researcher, Novo Nordisk researcher, Oxford Biomedica Researcher, or CRUK, Oxford-based investigators should submit the relevant non confidential Expression of Interest (EOI) online form for JJIF, NNIF, OXBIF, or CRHIF by 5pm on 31st July 2024. This EOI should provide a summary of the proposed project and anticipated outcomes, alongside a justification for support explaining how your proposal is aligned to the Johnson & Johnson, Novo Nordisk or Oxford Biomedica priority areas identified above. Jonhson & Johnson, Novo Nordisk and Oxford Biomedica will select proposals of interest and support the development of proposals. Funding provided will be in line with MLSTF, up to £85k per project with awards being made for direct costs only. It is anticipated that Johnson & Johnson, Novo Nordisk and Oxford Biomedica will each be co-funding two projects through this scheme in 2024.
For further information about the remit, application and award process for funding streams under the umbrella of MLSTF, please contact the TRO (translationalresearchoffice@medsci.ox.ac.uk). |
|
|
|
Other Funding Opportunities
|
| |
|
|
|
| UKRI Cross Research: Round 2 |
| |
|
UKRI has announced round 2 of the Cross-Research Council Responsive Mode Pilot Scheme. They will fund two-year projects in the range of £200k - £1.2m that are novel, interdisciplinary and cross-Council research. Projects where there is a clear “lead” Research Council, or where the interdisciplinary research outcomes are limited, will not be eligible for this scheme. Oxford can submit a maximum of 20 applications to the scheme, therefore Research Services are running the internal selection process to select the applications.
Lead applicants are invited to submit an Expression of Interest form (EoI) through IRAMS by 12 noon on Monday 16 September 2024. Please direct any queries to srd.team@admin.ox.ac.uk |
|
|
|
|
|
|
|
|
| The MRC has pre-announced Round 3 of the MRC Centres of Research Excellence funding call. CoREs are funded for up to 14 years with initial bids requesting up to £21m over seven years. In round 3 the University may only lead on one CoRE application that can be in any field of medical research. MSD is running a two-stage internal process to select Oxford’s application to round 3. If you are interested in leading Oxford’s single CoRE bid in round 3, or if you are exploring a collaboration where another institution is likely to lead the CoRE with Oxford as a major partner, you must submit an internal stage 1 application in IRAMS by 12 noon on Wednesday 18 September 2024. Please direct questions to research@medsci.ox.ac.uk. |
|
|
|
|
| |
| |
|
|
|
|
| Industry Insights Seminar |
| |
|
5 September 2024 | Online Only | 12pm
Title: Prevention is better than cure – realising a sustainable new paradigm to predict and pre-empt obesity and its consequences
Speaker: Professor Nadeem Sarwar (Corporate Vice President, Co-Founder and Head, Transformational Prevention Unit)
Company: Novo Nordisk |
|
|
|
|
| |
| |
|
|
|
|
| New Therapeutic Approaches in Translational Mental Health |
| |
|
16 September 2024 | Maths Institute | All day
This in-person conference is hosted by the Oxford Health BRC and sponsored by the UK Mental Health Mission. The event aims to bring together industry, academic & clinical researchers, the regulator and government research funding organisations to discuss the current challenges facing therapeutic development. The overall objective is to forge collaborations that can increase capacity and capability through partnerships to deliver paradigm changes in translational mental health research. The event includes keynotes, lightning talks, roundtable discussion and industry led workshop sessions by Angelini Pharma, Big Health, Boehringer Ingelheim, Karuna Therapeutics and Reckitt Benckiser. |
|
|
|
|
| |
| |
|
|
|
|
| Why are so many of us burnt out, and what we can do about it? |
| |
|
26 September 2024 | Online only | Seminar 11-12; Workshop 13.30 to 15.00
Why do ever more of us find it so hard to find a good balance between life and work? The dramatic rise of work-related suffering is clearly not the problem of just a handful of people who are bad at time management.
This seminar will explore some of the deeper cultural reasons for why we are all so burnt out and offer some practical, actionable advice on what we can do about our exhaustion and how we can re-learn how to thrive.
Sign up for the Seminar here: https://forms.office.com/e/0cyFgdacJp
Sign up for the workshop here: https://forms.office.com/e/vwFNxaUq37 |
|
|
|
|
| |
| |
|
Can you help these trials?
|
| |
|
|
|
|
|
| Oxford Vaccine Group would like to invite you to take part in a study investigating how two common respiratory germs alter the environment in your nose and impact human health. The knowledge gathered in this project could be used to help develop new interventions such as anti-virus agents and drugs targeting the host body response. If you are 18 to 55 years old, you may be eligible to take part. We will provide reimbursement for your time, inconvenience and travel. The study duration is approximately 10 weeks. If you would like to find out more, please read the Participant Information Sheet. If you are interested in joining the study, please visit the Pre-screening Questionnaire via the link below. |
|
|
|
|
|
|
|
| We need volunteers for a new vaccine against Marburg virus |
| |
|
| If you are aged 18 to 55 years old and in good health, then you may be eligible to take part in a study investigating a new vaccine against Marburg virus. All participants will be reimbursed up to £1290 for their time, inconvenience, and travel. For further information please click on the link below. Here is a link to pre-screening questionnaire: Pre-screening Questionnaire or contact Oxford Vaccine Group with any questions: Email: info@ovg.ox.ac.uk Tel: 01865611400. |
|
|
|
|
|
|
|
|
|
| Oxford Vaccine Group would like to invite you to take part in a study in a challenge study to find a vaccine against malaria. The total study participation time is 18 months. If you would like any further information regarding the study please contact info@ovg.ox.ac.uk, or call 01865 611400 |
|
|
|
|
|
|
|
|
|
| Oxford Vaccine Group is looking for volunteers to help us understand how our immune systems respond to repeated infection with malaria. By taking part in this challenge study, you could help the research aimed at preventing hundreds of thousands of child deaths. If you are aged 18 to 45 years old, in good health and live in the Thames Valley, then you may be eligible to take part in the BIO-004 study. All participants will be reimbursed for their time, inconvenience and travel up to £9,100. |
|
|
|
|
|
|
|
|
|
